A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients
Launched by CHUGAI PHARMACEUTICAL · Aug 1, 2012
Trial Information
Current as of September 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have a diagnosis of probable AD dementia, based on NINCDS/ADRDA criteria
- • Meet DSM-IV criteria for Dementia of the Alzheimer type
- • MMSE score : 16 to 26 etc.
- Exclusion Criteria:
- • Meet the exclusion criteria of MRI at screening.
- • A history of significant neurodegenerative diseases or dementia other than Alzheimer's disease.
- • etc.
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd. is a leading research-based pharmaceutical company headquartered in Tokyo, Japan, renowned for its commitment to innovation and excellence in healthcare. A member of the Roche Group, Chugai specializes in the development of innovative therapeutics, particularly in oncology, immunology, and rare diseases. The company is dedicated to advancing medical science through robust clinical research and collaboration with healthcare professionals, aiming to deliver high-quality, effective treatments that enhance patient outcomes and improve quality of life. With a strong focus on precision medicine and a rich pipeline of novel therapies, Chugai Pharmaceutical is at the forefront of addressing unmet medical needs globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tohoku, Japan
Kyushu, Japan
Kansai, Japan
Kanto, Japan
Toakai, Japan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials